You have been successfully logged out.
Patient selection and CAR T-cell therapy 5 years on
CAR T-cell therapy was launched in the UK over 5 years ago. Advancing treatment of some blood cancers, it is a novel and potentially curative therapeutic option that uses a patient’s own white blood cells to create a one-time treatment.1
The panel of experts will be discussing the clinical and non-clinical factors to take into consideration for referring patients for CAR T-cell therapy (specifically in DLBCL).
(Webinar recorded March 2024. Full video: 32 minutes)
DR WENDY OSBORNE
Consultant Haematologist, Freeman Hospital
DR ROBIN SANDERSON
Consultant Haematologist-Oncologist, King’s College Hospital
DR KAWAI YIP [SKYE]
(Referring Centre) Consultant Haematologist, Darent Valley Hospital
April 2025 UKI-YES-0115
Adverse events should be reported.
For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.